Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC) Feb 28, 2018
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study Feb 26, 2018
Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer Feb 20, 2018
Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond Feb 14, 2018
Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York Feb 7, 2018
Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study Jan 30, 2018
Heat Biologics Receives FDA Guidance at Type C Meeting for HS-110 Clinical Trial in the Treatment of Non-small Cell Lung Cancer Dec 7, 2017
